From tumor mapping to state-informed surgery: C4 and HOXA1 in ovarian cancer

To the Editor, The integration of single-cell and spatial transcriptomic profiling has refined the interrogation of ovarian cancer heterogeneity. The identification of the C4 (SAA1+) tumor program and an HOXA1-associated regulatory axis delineates a coherent tumor state[1]. As precision oncology shifts from static genomic classification toward therapy-responsive cellular programs, the key question is whether such states can inform perioperative decisions rather than remain descriptive findings. Single-cell atlases provide ecosystem snapshots, whereas surgical oncology is defined by temporal selection. Recurrence reflects evolutionary bottlenecks imposed by cytoreduction and systemic therapy. The emergence of C4 therefore requires a distinction between lineage persistence and state plasticity. Without patient-matched longitudinal anchoring, cross-sectional contrasts may conflate therapeutic selection with inter-patient heterogeneity[2]. If C4 survives therapeutic bottlenecks and concentrates within residual niches, it becomes a marker of residual disease biology with direct implications for surveillance and perioperative intensification. HOXA1 is presented as a transcriptional determinant of the C4 phenotype. The translational threshold is whether HOXA1 sustains the C4 state architecture rather than correlates with its expression profile. Because C4 integrates oxidative phosphorylation, GAS6–AXL signaling, and microenvironmental remodeling, HOXA1 perturbation should collapse the C4 module, reduce GAS6–AXL output, and shift oxidative metabolism[3]. A regulator of state maintenance would predict enrichment within treatment-exposed residual niches and define a rational target for post-therapy intervention. Integrating regulon inference with chromatin occupancy profiling and targeted perturbation can clarify direct transcriptional control, while functional metabolic and secretory assays would connect regulatory structure to therapeutic vulnerability[4]. The stromal-risk transcriptional signature (STRS) model translates state biology into prognostic stratification. Prognostic capacity alone, however, does not establish surgical utility. Absent incremental value beyond residual disease and HRD status, STRS remains descriptive rather than decision-directive[5]. For perioperative integration, thresholds must correspond to management pathways instead of continuous risk gradients. Prospective embedding within surgical workflows, linking preoperative risk assignment to resectability planning and postoperative surveillance, is necessary to demonstrate net clinical benefit and reproducibility. Alignment with biologically targetable C4-associated programs further determines whether STRS guides escalation or merely categorizes risk. More broadly, this work reflects a structural shift in oncology. Genomic alterations guide classification, yet recurrence and immune escape frequently arise from coordinated cellular programs that persist or re-emerge under selection pressure. Determining whether C4 is inducible and reversible or lineage-stable defines intervention timing. If tumor states can be longitudinally tracked and therapeutically modulated, precision oncology advances from molecular labeling toward temporal management of persistence programs. For surgical oncology, the value of spatial single-cell analysis will be measured not by resolution but by its capacity to recalibrate operative reasoning. By defining a C4-associated program linked to regulatory and prognostic features, this study provides a foundation for integrating molecular state assessment into perioperative risk modeling. The next imperative is longitudinal validation and demonstration of decision-grade incremental value. If achieved, tumor state evaluation may become an operational layer of surgical decision support that aligns molecular insight with therapeutic timing. Ethical approval Ethical approval was not required for this study as it did not involve human participants, patient data, or any procedures requiring ethical clearance. Consent This study did not involve human participants, patients, or volunteers; therefore, written informed consent was not required.